Research Press Releases

Latest Releases

Title	Date
Vernalis announces CCP-07 starts 12 month stability testing	11 June 2015
Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)	01 May 2015
Vernalis plc enters into research collaboration with Taisho Pharmaceutical Co., Ltd	07 April 2015
Vernalis and Asahi Kasei Pharma Achieve Research Milestone	06 March 2015
Vernalis licenses proprietary adenosine receptor antagonist technology, including lead compound V81444, for, development and commercialisation	26 February 2015
Unaudited interim results for the periods ended 31 December 2014	10 February 2015
Vernalis licenses V2006 to RedoxTherapies Inc for use in immuno-oncology	09 October 2014
Interim results for the six months ended 30 June 2014	05 August 2014
Vernalis and Servier achieve two Research Milestones in their Oncology Collaborations	04 August 2014
Vernalis and Servier achieve Research Milestone as BCL-2 inhibitor drug candidate enters Phase I	19 June 2014